Boehringer Ingelheim

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

Retrieved on: 
金曜日, 5月 10, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Patient, Egle, Daiichi Sankyo, University, Immune system, Bristol Myers Squibb, Therapy, Drug development, GSK, Boehringer Ingelheim, Kyowa Kirin, ADC, MBA, MD, MedImmune, Biophysics, Cancer, CMO, Third Rock Ventures, Carnegie Mellon University, Drug discovery, Acquisition, Amgen, OrbiMed, Business development, Eli Lilly, Roche, Column, Immunotherapy, AstraZeneca, IO, Master of Science, Pharmaceutical industry

“We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience.

Key Points: 
  • “We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience.
  • The appointment of Dr Motlagh is critical for Egle, as the company is moving to clinical development of assets in oncology and auto-immunity.
  • Pejvack will impact the future development of the rich pipeline at Egle, based on the modulation of regulatory T cells.
  • As CMO, Pejvack will drive the clinical and medical strategy and development of our Company in the years to come.

Boehringer Ingelheim expands access to adalimumab-adbm injection, the company's biosimilar to Humira®

Retrieved on: 
月曜日, 5月 13, 2024
Adalimumab, Partnership, Patient, Access, Purple, Pharmacy, Boehringer Ingelheim, Senior, Boehringer, Fine chemical

We're committed to helping the biosimilar market reach its potential, and this partnership is an important step in enabling greater adoption of these lower-cost options."

Key Points: 
  • We're committed to helping the biosimilar market reach its potential, and this partnership is an important step in enabling greater adoption of these lower-cost options."
  • Under the terms of the agreement, Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent.
  • Boehringer Ingelheim will continue to commercialize Boehringer Ingelheim-labeled Cyltezo® (adalimumab-adbm) injection and Adalimumab-adbm.
  • "We are pleased to be working with Boehringer Ingelheim to bring adalimumab-adbm to more patients.

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
木曜日, 5月 9, 2024
DAS, AMD, Boehringer Ingelheim, Research, Johnson & Johnson, Conference, Webcast, Conference call, Patient, M&A, CPT, Eye, Pharming, Conditional sentence, Data analysis, MBA, Drug delivery, Clinical trial, Biotechnology, ARVO, Visual acuity, Pharmaceutical industry

ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
  • License and other revenue for the first quarter of 2024 was $230,000, compared to $4,000 for the first quarter of 2023.
  • Other expense for the first quarter of 2024 was $1.5 million, compared to $0 for the first quarter of 2023.
  • Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Retrieved on: 
水曜日, 5月 8, 2024
Respiratory Research, Telecanthus, Liver disease, Boehringer Ingelheim, Publication, Research, Partnership, Development, Administration, ARVO, Therapy, Pulmonary fibrosis, Retina, Patient, Liver, Eye, Fibrosis, Regeneration, SWAP

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided first quarter 2024 financial results and business updates.

Key Points: 
  • Financial Results for the First Quarter Ended March 31, 2024
    Cash Position: Cash and cash equivalents were $27.3 million as of March 31, 2024, compared to $36.0 million as of December 31, 2023.
  • However, inclusive of proceeds from a financing completed in April 2024, the proforma cash for March 31, 2024 would be $43.2M.
  • Restructuring: Restructuring charges for the first quarter ended March 31, 2024 were zero, as compared to $1.2 million for the same period in 2023.
  • Net Loss: Net loss for the first quarter ended March 31, 2024 was $8.8 million, as compared to $14.3 million for the same period in 2023.

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia

Retrieved on: 
月曜日, 5月 6, 2024
Boehringer Ingelheim, Safety, Risk, Tissue, Diabetic retinopathy, Abstract, Research, Ingelheim am Rhein, Stanford School, Light, Principal, Master of Science, Paratriathlon, Geographic atrophy, Pediatrics, DMI, Quality of life, ARVO, DR, Medical device

Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI).

Key Points: 
  • Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI).
  • The current standard of care for advanced DR includes intravitreal anti-VEGF treatment or invasive laser treatment.
  • “Retinal non-perfusion is a key driver of vision loss in people living with diabetic retinopathy.
  • However, until the HORNBILL study, retinal non-perfusion has not been explored as a potential treatment target.”
    “Vision loss associated with retinal conditions such as diabetic retinopathy and DMI has a devastating impact on quality of life.

Dr. Reginald Seeto Appointed as CEO and President, to Lead Scipher Medicine's Next Phase of Growth

Retrieved on: 
木曜日, 5月 9, 2024
Research, General Health, Networks, Pharmaceutical, Data Management, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Other Technology, Health, Other Science, CFO, Jonathan Rothberg, McKinsey & Company, Boehringer Ingelheim, MBBS, EVP, Khosla Ventures, Growth, Medicine, Corporate development, MedImmune, Autoimmune disease, Audit committee, Patient, Rheumatoid arthritis, Reg, Independent, AstraZeneca, Management

Scipher Medicine, an AI-enabled precision immunology company, today announced the appointment of Reginald Seeto, MBBS*, as Chief Executive Officer and President.

Key Points: 
  • Scipher Medicine, an AI-enabled precision immunology company, today announced the appointment of Reginald Seeto, MBBS*, as Chief Executive Officer and President.
  • Dr. Seeto is a seasoned CEO and Board Member who brings more than two decades of leadership experience across both diagnostic and therapeutic companies.
  • Dr. Seeto was most recently the CEO and President of CareDx ("CDNA"), a company focused on the transplant patient.
  • Seeto and Muir’s appointment mark a significant step forward for Scipher as the company positions itself for continued growth within the field of precision immunology.

Klick Health Wraps First Round of $1,000,000 Klick AI Prize, Awarding First $200,000 to Three Teams

Retrieved on: 
火曜日, 5月 7, 2024
Other Science, Pharmaceutical, Research, Artificial Intelligence, Science, Social Media, Technology, Digital Marketing, General Health, Public Relations, Investor Relations, Marketing, Advertising, Health, Content Marketing, Communications, Media, Apps, Applications, Health Technology, Corporate title, Boehringer Ingelheim, ChatGPT, News, Social media, AI, Mayo Clinic Proceedings, Swedish Orphan Biovitrum, Thought, Click, Human, Novartis, Digital health, Type 2 diabetes, Medicine, Bristol Myers Squibb, Sanofi

One of these entries, a unique, personalized AI training idea for pharma sales reps, was developed by some Client Success team members.

Key Points: 
  • One of these entries, a unique, personalized AI training idea for pharma sales reps, was developed by some Client Success team members.
  • Round two of the Klick Prize is now open and the judges will reconvene this summer.
  • Today’s news is the latest in the company’s ongoing AI and machine-learning innovations created to help Klick clients and team members achieve even greater success..
  • At the prestigious NeurIPS conference in December, it unveiled LOVENet TM , an AI framework that rapidly identifies new uses for existing drugs.

Trialbee to Showcase Power of Data-Driven Clinical Trial Recruitment During Upcoming Webinars and Conferences

Retrieved on: 
水曜日, 5月 8, 2024
Honey, Patient, LEGO, ROI, Ecosystem, Learning, Participation, Hyatt Regency Barcelona Tower, AI, Marketing, Parexel, Boehringer Ingelheim, Artificial intelligence, Software as a service, Success, PRP, ChromeOS, GSK, Valley Forge Casino Resort, Pharmaceutical industry

WILMINGTON, Del., and MALMÖ, Sweden, May 8, 2024 /PRNewswire-PRWeb/ -- Trialbee, the global leader in technology-driven patient recruitment for clinical trials, will host two webinars and participate in three industry conferences in May to showcase its data-driven, personalized approach to identifying and engaging participants for research studies.

Key Points: 
  • For more information and to register…
    "Improve Site Pull-Through of Global Patient Referrals."
  • On May 15 at 10am ET, join Trialbee Director of Customer Delivery Sarah Evans and Product Manager Oskar Daniel to dive into recruitment funnels and demonstrate how data from a centralized Patient Recruitment Platform (PRP) results in high-quality, motivated patients being referred to clinical trial sites.
  • Trialbee is changing global patient recruitment with the Honey Platform™, a vendor-agnostic and stand-alone platform that provides unprecedented transparency, actionable data insights, and reliable return-on-investment (ROI) reporting.
  • For more information about how Trialbee is revolutionizing the patient recruitment ecosystem through technology, people, and passion, visit https://www.trialbee.com/ .

Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats

Retrieved on: 
火曜日, 5月 7, 2024
Hyperglycemia, Insulin, DOI, Boehringer Ingelheim, Pet, Veterinarian, Health, Animal, Research, SJM, Diabetes, Health Canada, Trigger, Vaccine, Farmer, Needle, Cat, Human, Veterinary medicine, Livestock, Food, Diagnosis, Boehringer, Diabetes in cats, Euthanasia, Horse, Report

SENVELGO™ (velagliflozin oral solution) is the first once-daily liquid oral solution to improve glycemic control in newly diagnosed cats with diabetes mellitus.

Key Points: 
  • SENVELGO™ (velagliflozin oral solution) is the first once-daily liquid oral solution to improve glycemic control in newly diagnosed cats with diabetes mellitus.
  • SENVELGO™ is the first once-daily liquid oral solution for the reduction of hyperglycemia in cats with non-insulin-dependent diabetes mellitus.
  • Pet owners can give the once-daily liquid oral solution with a small amount of food or directly into the cat's mouth.
  • Dr. Walt Ingwersen, Technical Services Veterinarian with Boehringer Ingelheim Canada, said SENVELGO™ revolutionizes the treatment and management of feline diabetes in newly diagnosed cats.

Boehringer Ingelheim Unveils New R&D Laboratory in St. Joseph, Mo., Pioneering the Future of Animal Health Products

Retrieved on: 
金曜日, 5月 3, 2024
Health, Animal, Heart, Boehringer, Horse, Research, Livestock, Boehringer Ingelheim, Corridor, Fine chemical

ST. JOSEPH, Mo., May 3, 2024 /PRNewswire/ -- Boehringer Ingelheim, a global leader in animal health, celebrated a new and innovative laboratory space at its St. Joseph, Mo.

Key Points: 
  • ST. JOSEPH, Mo., May 3, 2024 /PRNewswire/ -- Boehringer Ingelheim, a global leader in animal health, celebrated a new and innovative laboratory space at its St. Joseph, Mo.
  • This state-of-the-art facility is set to revolutionize the development of future products, including biotherapeutics.
  • This location is primarily dedicated to the product development and production of animal health products for livestock and horses.
  • "Boehringer Ingelheim is not just a global leader in animal health – they are a part of the fabric of our community," said Kim Young, President KC Animal Health Corridor.